PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with...

Descripción completa

Detalles Bibliográficos
Autores principales: Marayati, Raoud, Stafman, Laura L., Williams, Adele P., Bownes, Laura V., Quinn, Colin H., Aye, Jamie M., Stewart, Jerry E., Yoon, Karina J., Anderson, Joshua C., Willey, Christopher D., Beierle, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966748/
https://www.ncbi.nlm.nih.gov/pubmed/33727604
http://dx.doi.org/10.1038/s41598-021-85289-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966748/
https://www.ncbi.nlm.nih.gov/pubmed/33727604
http://dx.doi.org/10.1038/s41598-021-85289-0

Ejemplares similares